PEPTIDE

Thymosin ±17 (Zadaxin)

28-residue immunomodulatory peptide; promotes T-cell maturation via TLR signaling. Approved in 35+ countries (not FDA) for hepatitis indications.

BIOGATE · GREEN | POSTERIOR 32.0% | MW 3108.3 | 28AA

SEQUENCE

SDAAVDTSSEITTKDLKEKKEVVEEAEN

Modifications: acetylated N-terminus

PDA-V1 chain of custody

Outer hash

`d78ff64cd88ff7dfd98ff972da8ffb05d38ff000d48ff193d58ff32`

Merkle root

`2-a878d6929878bd628878a43278788b02e8793b52d8792222c87908f2b878efc`

Inputs

`8-c144ecc8d14505f8e1451f28f1453858814488089144a138a144ba6`

TEE attestation

`6-c800b676b8009d46e800e8d6d800cfa6880051b678003886a800841698006ae`

Living Outcome Oracle

± =24.9 ² =53.0 **P(success) = 32.0%** 95% CI [20.0%, 44.0%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE B — 2007 · Curr Opin Pharmacol

Thymosin alpha 1: a historical overview

Garaci E et al.

PMID 17683988